Position in INSM
as of Mar 31, 2026
· filed May 15, 2026
Position Value
$48,333,078
New position
Shares Held
295,579
first reported quarter
Ownership
0.136%
of shares outstanding
% of Portfolio
0.25%
of 13F equity value
Holder Rank
—
not a current holder
Holding Since
Mar 2026
1 quarter on record
Voting authority
Sole 100.ToString("F0")%
Shared 0.ToString("F0")%
None 0.ToString("F0")%
Position in Biotechnology
Healthcare · as of Mar 31, 2026Bridgewater Associates, LP holds $275,081,004 across 28 Biotechnology names. INSM ranks #1 (17.6% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | INSM |
INSMED Inc
This page
|
295,579 | $48,333,078 | |
| 2 | ALNY |
Alnylam Pharmaceuticals, Inc.
|
106,592 | $35,268,095 | |
| 3 | HALO |
Halozyme Therapeutics, Inc.
|
511,429 | $33,053,656 | |
| 4 | EXEL |
Exelixis, Inc.
|
480,996 | $20,629,918 | |
| 5 | BBIO |
BridgeBio Pharma, Inc.
|
259,459 | $19,267,425 | |
| 6 | REGN |
Regeneron Pharmaceuticals, Inc.
|
22,724 | $17,557,471 | |
| 7 | INCY |
Incyte Corp
|
130,296 | $12,263,459 | |
| 8 | KRYS |
Krystal Biotech, Inc.
|
46,367 | $11,977,523 |
All Filings in INSM
Export CSV
1 filing row on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-03-31 | $48,333,078 | 295,579 | Shares | Sole | 2026-05-15 | |
| No filing history on record for this holder in this stock. | ||||||